Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
|Articles|January 11, 2019
Update on the ELIANA trial (VIDEO)
Author(s)Bobby Lazzara, MD
For Contemporary Pediatrics, Dr Bobby Lazzara discusses the latest data on the effectiveness of CAR T-cell therapy from the ELIANA trial, which was presented at the 2018 American Society of Hematology annual meeting in San Diego, California.
Advertisement
For Contemporary Pediatrics, Dr Bobby Lazzara discusses the latest data on the effectiveness of CAR T-cell therapy from the ELIANA trial, which was presented at the 2018 American Society of Hematology annual meeting in San Diego, California.
Advertisement
Related to this article
Learn when your baby is ready for solids, choose safe purees or finger foods, prevent choking, prioritize iron, and introduce allergens confidently.
Christina Boull, MD, shares recommendations for infant skin care, including choosing gentle cleansers, avoiding irritants, and supporting the skin barrier.
Completing the DTaP primary series was 96.2% effective against pertussis in Alaska children aged 6 months to 6 years during a record 2024 outbreak.
Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva for childhood-onset INS and its implications for relapse prevention and pediatric care.
Hai D. Nguyen-Tran, MD, discusses clinical signs, neurologic warning symptoms, supportive care, and preventing the spread of hand, foot, and mouth disease.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Hand, foot, and mouth disease: Red flags pediatricians should know
2
FDA approval of Gazyva offers new option for pediatric INS
3
DTaP 96% effective against pertussis in Alaska outbreak
4
FDA sets new PDUFA date for Anaphylm for type I allergic reactions
5